Recent Advances in the Treatment of Non-Hodgkin’s Lymphomas

Restricted access

Non-Hodgkin’s lymphomas (NHL) represent a diverse set of diseases, with different treatment pathways based on the stage and type of hematologic cancer. In their presentation at the NCCN 18th Annual Conference, Dr. Jeremy Abramson and Dr. Andrew D. Zelenetz discuss 3 specific B-cell NHLs: follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. They provided an overview of the treatment strategies for patients with these hematologic malignancies, and offered highlights from recent clinical trials supporting these recommendations.

Correspondence: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center, Yawkey Center for Outpatient Care, Mailstop: Yawkey 9A, 32 Fruit Street, Boston, MA 02114. E-mail: jabramson@partners.orgDr. Abramson has revealed that he has served as a consultant for Seattle Genetics. Dr. Zelenetz has revealed that he receives clinical research support from Abbott Laboratories; Celgene Corporation; Cephalon, Inc.; Genentech, Inc.; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.; Allos Pharm; Calistoga, Pharmacyclics; Plexxikon; Roche; and Seattle Genetics and serves on an advisory board or as a consultant for Abbott Laboratories; Celgene Corporation; Cell Therapeutics, Inc.; Cephalon, Inc.; Genentech, Inc.; GlaxoSmithKline; Allos; Cancer Genetics; Gilead; Seattle Genetics; Roche Laboratories, Inc.; and sanofi-aventis U.S.Andrew D. Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065. E-mail: a-zelenetz@ski.mskcc.org
  • 1.

    FedericoMLuminariSDondiA. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: final results of FOLL05 trial from the FondazioneItalianaLinfomi (FIL). J ClinOncol2013; in press.

    • Search Google Scholar
    • Export Citation
  • 2.

    RummelMJNiederleNMaschmeyerG. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicenter, randomized, phase 3 non-inferiority trial. Lancet2013; in press.

    • Search Google Scholar
    • Export Citation
  • 3.

    SallesGSeymourJFOffnerF. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet2011;377:4251.

    • Search Google Scholar
    • Export Citation
  • 4.

    LeonardJJungS-HJohnsonJL. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma [abstract]. J ClinOncol2012;30(Suppl): Abstract 8000.

    • Search Google Scholar
    • Export Citation
  • 5.

    GeislerCHKolstadALaurellA. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol2012;158:815816.

    • Search Google Scholar
    • Export Citation
  • 6.

    HermineOHosterEWalewskiJ. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [abstract]. Blood2012;120: Abstract 151.

    • Search Google Scholar
    • Export Citation
  • 7.

    Kluin-NelemansHCHosterEHermineO. Treatment of older patients with mantle-cell lymphoma. N Engl J Med2012;367:520531.

  • 8.

    RummelMJNiederleNMaschmeyerG. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. Lancet2013; in press.

    • Search Google Scholar
    • Export Citation
  • 9.

    HallekMChesonBDCatovskyD. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111:54465456.

    • Search Google Scholar
    • Export Citation
  • 10.

    WierdaWGO‘BrienSWangX. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J ClinOncol2011;29:40884095.

    • Search Google Scholar
    • Export Citation
  • 11.

    MillerMDParadisCFHouckPR. Rating chronic medial illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res1992;41:237248.

    • Search Google Scholar
    • Export Citation
  • 12.

    HallekMFischerKFingerle-RowsonG. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial. Lancet2010;376:11641174.

    • Search Google Scholar
    • Export Citation
  • 13.

    ByrdJCFurmanRRCoutreS. The Bruton‘s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study [abstract]. Blood2012;120: Abstract 189.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 137 137 17
PDF Downloads 13 13 1
EPUB Downloads 0 0 0